Access Digital Health
CountriesSignalsInterventionsToolsAbout
Log in
← Interventions

Respiratory syncytial virus (RSV) prevention

Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
—
no $/DALY
GiveWell
—
no GiveWell model
CE sources
1
Tier B · 18 studies
Source agreement
—
single source
Loading effectiveness evidence…
Cost-effectiveness

Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.

Published study estimates ($/DALY)Tier B · context only

Tufts GHCEA · 18 studies, varied methods — explore the spread, not a single number.

Health-system
$1,377
median · n=12
Societal
$317,325
median · n=6
Filter the cohort
$1,537median of 18 studies · IQR $1,319–$224,917

No standardized benchmark available — only published studies with varied methods.

Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Delivery readiness is country-specific. Select a country in the selector above to see its health-system context — workforce density, financing mix, service coverage.
The figures above are published benchmarks. To build an investment case for your own context — local unit costs, target population, coverage assumptions — model it directly. Select a country first to carry its context into the model.
Choose a country to model →
Looking for supply/market data for Respiratory syncytial virus (RSV) prevention? Select a country above, then open its intelligence page.